2025 Germany Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 Germany Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in Germany are Bayer AG, Novartis AG, Roche Holding AG, and Regeneron Pharmaceuticals, Inc. Bayer AG is a German multinational headquartered in Leverkusen, Germany, and markets Eylea, an FDA-approved drug for neovascular AMD. Novartis, based in Basel, Switzerland, is involved in cutting-edge gene therapy clinical trials targeting AMD. Roche AG, also Swiss-based, is involved in extensive diagnostics and therapeutics for AMD, holding a significant global presence. Regeneron, headquartered in the US, collaborates on novel monoclonal antibody treatments for AMD and is active in the German market through clinical trials and sales.
These companies drive the German AMD therapeutics market, estimated at around $395 million in 2022 and expected to reach $684 million by 2030, with a CAGR of 7.1%. Germany’s aging population contributes to increased AMD prevalence, creating substantial demand for innovative treatments. Government and private investments support advanced research, including gene therapy and AI-assisted diagnostics at institutions like Universitäts-Augenklinik Würzburg. The integration of AI technology enhances diagnosis and disease monitoring, complementing pharmaceutical efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in Germany are Bayer AG, Novartis AG, Roche Holding AG, and Regeneron Pharmaceuticals, Inc. Bayer AG is a German multinational headquartered in Leverkusen, Germany, and markets Eylea, an FDA-approved drug for neovascular AMD. Novartis, based in Basel, Switzerland, is involved in cutting-edge gene therapy clinical trials targeting AMD. Roche AG, also Swiss-based, is involved in extensive diagnostics and therapeutics for AMD, holding a significant global presence. Regeneron, headquartered in the US, collaborates on novel monoclonal antibody treatments for AMD and is active in the German market through clinical trials and sales.
These companies drive the German AMD therapeutics market, estimated at around $395 million in 2022 and expected to reach $684 million by 2030, with a CAGR of 7.1%. Germany’s aging population contributes to increased AMD prevalence, creating substantial demand for innovative treatments. Government and private investments support advanced research, including gene therapy and AI-assisted diagnostics at institutions like Universitäts-Augenklinik Würzburg. The integration of AI technology enhances diagnosis and disease monitoring, complementing pharmaceutical efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
